News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Influenza Vaccine Market Outlook 2022”, the influenza vaccine has gained huge popularity in past couple of years due to frequent life threatening influenza outbreaks. The major growth drivers of the industry are growing healthcare expenditure, increasing awareness, tough competition, rising disposable income and huge government support.
 
A number of companies in the influenza vaccine business have collaborated with each other to develop vaccines to prevent seasonal as well pandemic influenza virus. For Instance: Sanofi Pasteur, the vaccines division of Sanofi, collaborated with researchers at the University of Georgia, to develop a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models. The vaccine is being developed by using a “Computationally Optimized Broadly Reactive Antigen”, or COBRA , technique, which will not only protect against multiple different strains of H1N1 virus at once but will also protect against many strains of seasonal influenza over several years.
 
Additionally, collaboration between vaccine and vaccine delivery Companies is an emerging trend in the influenza vaccine market as vaccine manufacturing companies are entering into contracts with drug delivery system manufactures to make complementary products, which cannot be used without each other.
 
For example, bioCSL, selling its influenza vaccine under the brand name Seqirus, has collaborated with the jet injector company, PharmaJet, to deliver influenza virus vaccine to people through jet injectors rather than traditional needle injections. The US food and Drug Administration (FDA) approved use of PharmaJet Stratis 0.5ml Needle-free Jet Injector for delivery of AFLURIA, (a vaccine for protection against  influenza virus A (H1N1) and (H3N2) as well as one influenza B virus, by bioCSL Inc.) in individuals from 18 through 64 years of age in the US. Vaccination using the jet injector method provides similar level of immune protection as flu vaccine administered via traditional flu shot.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM833.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm